ENTITY
Venus Medtech (Hangzhou)

Venus Medtech (Hangzhou) (2500 HK)

111
Analysis
Health Care • China
Venus Medtech is a leading medical device company specializing in transcatheter structural heart valvular therapies. It develops and commercializes innovative solutions for all four heart valves (TAVR, TPVR, TMVR, TTVR) and interventional hypertension treatment. The company was founded in 2009 and is headquartered in Hangzhou, China.
more
•16 Jun 2020 19:19

Hygeia Healthcare IPO (Part I): A Better Healthcare

Hygeia Healthcare is an oncology healthcare service provider in China who operates hospitals as well as provides third-party radiotherapy services...

Share
bullish•Kangji Medical
•16 Jun 2020 00:25

Kangji Medical IPO: Valuation Insights

Kangji Medical (1498779D CH) is the largest domestic minimally invasive surgical instruments and accessories (MISIA) platform in China, with a 2.7%...

Logo
520 Views
Share
•11 Jun 2020 16:58

Venus Medtech Lock-Up Expiry: Could Face Selling Pressure

Venus Medtech is a dominant player in the heart valve replacement (TAVR) market in China and was listed in Hong Kong on December 10th. Since...

Logo
601 Views
Share
bullish•Kangji Medical
•11 Jun 2020 11:27

Kangji Medical (康基医疗) Pre-IPO: COVID-19 Impacts and Thoughts on Valuation

Kangji Medical is a domestic leader in minimally invasive surgery devices. It has three main product types, trocars, polymer ligation clips, and...

Logo
757 Views
Share
bullish•Peijia Medical
•14 May 2020 13:27

Peijia Medical IPO: Trading Debut Equals First-Day Pop?

Peijia Medical (9996 HK) is a leading transcatheter heart valve medical device company in China. Peijia will commence trading on Friday, 15 May. At...

Logo
444 Views
Share
x